Alpha Tau Medical shares surge 63.83% after-hours after first patient treated in glioblastoma pilot study using Alpha DaRT.

Alpha Tau Medical surged 63.83% in after-hours trading following the announcement that the first patient was treated with its Alpha DaRT® technology for recurrent glioblastoma in a pilot study. The treatment, conducted at The Ohio State University, marks a milestone in the company’s development of its alpha-radiation therapy, which targets tumors while minimizing damage to healthy brain tissue. The news highlights regulatory support, including FDA Breakthrough Device Designation, and underscores the therapy’s potential to address a critical unmet need in treating aggressive cancers with poor survival rates. The pilot study’s focus on feasibility and safety, coupled with the successful first procedure, likely fueled investor optimism about the technology’s commercial prospects and accelerated regulatory pathways.